Eriglip M Forte 1000mg/20mg Tablet is a combination oral antidiabetic medication containing Metformin hydrochloride 1000mg and Teneligliptin 20mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization, thereby reducing hyperglycemia. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the activity of incretin hormones, which increase insulin secretion in a glucose-dependent manner and suppress glucagon release, contributing to improved glycemic control. The fixed-dose combination offers complementary mechanisms of action, targeting multiple pathophysiological defects in type 2 diabetes. Eriglip M Forte is typically prescribed when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is recommended to be administered orally with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of renal function is essential. Common adverse effects may include gastrointestinal disturbances, hypoglycemia (particularly when used with other antidiabetic agents), and rare hypersensitivity reactions. This formulation facilitates improved patient compliance by reducing pill burden in the management of type 2 diabetes.